Phaseline

Companies › JW Pharmaceutical

JW Pharmaceutical: clinical trials, targets and expected readouts

7 active drug programs in 16 registered trials: 9 Phase 4, 3 Phase 1, 3 Phase 3, 1 Phase 2; Metabolic and endocrine, Other, Cardiovascular, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pitavastatin
HMG-CoA reductase inhibitor
HMGCRPhase 4Hypercholesterolemia; Dyslipidemias; ASCVD; Primary Prevention …Nov 2026
Anagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 4Type 2 Diabetes Mellitus (T2DM)Mar 2027
Empagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 4Type 2 Diabetes Mellitus (T2DM)Mar 2027
Linzagolix (KLH-2109)
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 3MenorrhagiaMar 2028
JW0104+C2402–Phase 3Hypertension–
JW0061–Phase 1HealthyDec 2026
JW2286–Phase 1Healthy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05537948PitavastatinPhase 4DyslipidemiasMetabolic and endocrineJan 2024
NCT06703710JW2286Phase 1HealthyOtherNov 2025
NCT06643130JW0104+C2402Phase 3HypertensionCardiovascularApr 2026
NCT06643130JW0104+C2402Phase 3HypertensionCardiovascularApr 2026
NCT07442630PitavastatinPhase 4HypercholesterolemiaMetabolic and endocrineNov 2026
NCT07442630PitavastatinPhase 4HypercholesterolemiaMetabolic and endocrineNov 2026
NCT07514780JW0061Phase 1HealthyOtherDec 2026
NCT07549958PitavastatinPhase 1Pancreatic CancerOncologyMar 2027
NCT07442006EmpagliflozinPhase 4Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineMar 2027
NCT07442006EmpagliflozinPhase 4Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineMar 2027
NCT07442006AnagliptinPhase 4Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineMar 2027
NCT07460960PitavastatinPhase 2Erectile Dysfunction Due to Arterial DiseaseCardiovascularDec 2027
NCT07378098Linzagolix (KLH-2109)Phase 3MenorrhagiaGenitourinaryMar 2028
NCT06767774PitavastatinPhase 4ASCVDMetabolic and endocrineAug 2029
NCT06722521PitavastatinPhase 4Primary PreventionCardiovascularJun 2032
NCT06722521PitavastatinPhase 4Primary PreventionCardiovascularJun 2032

Targets

GNRHR (1) HMGCR (1) SLC5A2 (1) DPP4 (1)

Companies with the same targets

AstraZeneca LG Chem Amgen AbbVie Pfizer TerSera Therapeutics Qilu Pharmaceutical Zhuhai Huahaikang Pharmaceutical Technology Kissei Pharmaceutical Changchun GeneScience Pharmaceutical

Companies built like this

Shenzhen Salubris Pharmaceuticals Boryung Pharmaceutical CSPC Ouyi Pharmaceutical Shanghai Minwei Biotechnology Beijing QL Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.